Novo Nordisk (NYSE:NVO) is planning a comprehensive launch of its oral semaglutide in the United States at the start of 2026, the company’s head of product and portfolio strategy confirmed on Wednesday.
Speaking to Reuters, Products and Portfolio Strategy Chief Helfgott highlighted that the company sees a “very compelling offer” with its Wegovy pill compared with Eli Lilly’s obesity treatment.
Helfgott also referred to the ongoing semaglutide trial for Alzheimer’s disease as “a lottery ticket,” underscoring the uncertainty surrounding this line of research.
Oral semaglutide marks a significant expansion of Novo Nordisk’s portfolio in weight management and diabetes care, providing patients with a potential alternative to injectable options.
This content is for informational purposes only and does not constitute financial, investment, or other professional advice. It should not be considered a recommendation to buy or sell any securities or financial instruments. All investments involve risk, including the potential loss of principal. Past performance is not indicative of future results. You should conduct your own research and consult with a qualified financial advisor before making any investment decisions.